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E-mail address: ipolikarpov@if.sc.usp.br (I. PolikarInterleukin-22 (IL-22) plays an important role in the regulation of immune and inﬂammatory
responses in mammals. The IL-22 binding protein (IL-22BP), a soluble receptor that speciﬁcally binds
IL-22, prevents the IL-22/interleukin-22 receptor 1 (IL-22R1)/interleukin-10 receptor 2 (IL-10R2)
complex assembly and blocks IL-22 biological activity. Here we present the crystal structure of
the IL-22/IL-22BP complex at 2.75 Å resolution. The structure reveals IL-22BP residues critical for
IL-22 binding, which were conﬁrmed by site-directed mutagenesis and functional studies. Compar-
ison of IL-22/IL-22BP and IL-22/IL-22R1 crystal structures shows that both receptors display an over-
lapping IL-22 binding surface, which is consistent with the inhibitory role played by IL-22 binding
protein.
Structured summary:
MINT-7010533: IL-22 BP (uniprotkb:Q969J5) and IL-22 (uniprotkb:Q9GZX6) bind (MI:0407) by X-ray crys-
tallography (MI:0114)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction proteins in human keratinocytes [9] and in lung and gut mucosaeInterleukins (ILs) are cytokines that regulate a variety of physi-
ological and pathological conditions such as normal and malignant
cell growth, as well as immune and inﬂammatory responses, which
makes them obvious targets for clinical applications [1,2]. Some
cytokines have pro-inﬂammatory activities, whereas others pro-
mote healing by reducing inﬂammation. Among these cytokines,
interleukin-22 (IL-22) is involved in the generation of inﬂamma-
tory and immune responses that lead to the development of sev-
eral illnesses such as Crohn’s disease [3], interstitial lung disease
[4], rheumatoid arthritis [5], and psoriasis [6]. On the other hand,
IL-22 has a protective role in liver injury by promoting hepatocyte
survival [7,8]. IL-22 also induces the production of antimicrobialchemical Societies. Published by E
tein; IL-22, interleukin-22; IL-
-10 receptor 2; IL-10, inter-
ember 9; CRF2-4, the second
kine receptor family class 2
2; ORF, open reading frame;
S, ﬂuorescent automatic cell
t mean square deviation; IL-
II domain
pov).from mice [10]. Taken together, these ﬁndings point out that IL-22
is involved in innate pathogen defense, wound healing, and regula-
tion of tissue inﬂammation by mediating the cross talk between
the immune system and epithelial cells [11].
Interleukin-22 is a member of the interleukin 10 (IL-10) super
family of cytokines and it is produced by activated NK and T cells
[12,13]. Nevertheless, a distinct lineage of T helper type 17 cells
(TH17 lineage) expressing IL-22 has recently been identiﬁed [14].
Human IL-22 is a 20 kDa-a-helical protein that signals through
its binding to class II cytokine family cell surface receptors, inter-
leukin-22 receptor 1 (IL-22R1) (cytokine receptor family class 2
member 9, CRF2-9) and interleukin-10 receptor 2 (IL-10R2) (the
second chain of the IL-10 receptor complex, CRF2–4) [15]. While
IL-10R2 is ubiquitously expressed, the IL-22R1 is expressed in a
limited number of normal tissues such as skin, kidney, liver, colon,
small intestine, lung, and pancreas [9,15]. IL-22 ﬁrst associates
with the extracellular domain of IL-22R1 and subsequently with
the extracellular domain of IL-10R2, which binds to a speciﬁc sur-
face created by the interaction between IL-22 and the IL-22R1. This
results in the assembly of a cytokine receptor complex with higher
afﬁnity for IL-22 [16].
Very recently, the three-dimensional structures of the IL-22/IL-
22R1 complex, which were published independently by two differ-
ent groups [17,18], revealed that IL-22 has distinct binding sites forlsevier B.V. All rights reserved.
Table 1
Crystallographic and structural informationa.
Data collection parameters
Space group P41
Cell parameters (Å) a = b = 67.9, c = 172.5
Wavelength (Å) 1.43
Resolution limits (Å) 29.25–2.75 (2.85–2.75)
Completeness (%) 96.52 (98.6)
Redundancy 2.7 (2.5)
Rmerge (%)b 14.5 (50.7)
hI/r(I)i 4.82 (1.6)
Total number of reﬂections 51014 (7389)




Bond length mean deviation (Å) 0.010
Bond angles mean deviation () 1.358
Ramachandran plot (%)
Residues in most favored regions 88.8
Residues in additionally allowed regions 11.2
Residues in disallowed regions 0.0









iIiðhklÞ, where Ii is the intensity of the
ith observation of reﬂection hkl and hIðhklÞi is the weighted average intensity of
observations i of reﬂections hkl.
c Rfactor ¼
P kFoj  kjFck=
P jFo j, where Fo and Fc are the observed and calculated
structure factor amplitudes.
d Rfree is the same as Rfactor but only for 5% of the data randomly omitted from
reﬁnement.
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loops interact with IL-22 residues within helices A and F, and loop
AB, the IL-10R2 binding site is formed by IL-22 hot spot residues lo-
cated on helices A and D, as described previously [19]. Furthermore,
site-directed mutagenesis and functional studies showed that IL-
22R1 residues Lys58 and Tyr60 are crucial for IL-22 binding [17].
In addition to its cellular receptor, IL-22 binds to a 25 kDa-se-
creted protein termed interleukin-22 binding protein (IL-22BP)
(cytokine receptor family class 2 member 10 (CFR2-10) or IL-22
receptor subunit alpha-2 (IL-22Ra2)), which is highly expressed
in breast, placenta, skin, lungs, spleen, and colon [20–22]. IL-
22BP is a soluble receptor that lacks both trans-membrane and
intracellular domains, and it is highly related to the extracellular
domains of class II cytokine receptors IL-22R1 and IL-20Ra.
Cross-linking experiments showed that IL-22BP speciﬁcally binds
IL-22 with high afﬁnity. Thus, IL-22BP prevents the interaction of
IL-22 with the functional cell surface receptor complex and acts
as a natural IL-22 antagonist [20–22]. This antagonism may be
important for the regulation of inﬂammatory responses induced
by IL-22.
Here we describe the crystal structure of the IL-22/IL-22BP
complex at 2.75 Å resolution, which reveals the molecular basis
of IL-22 recognition by its decoy receptor. The importance of key
amino acid residues identiﬁed by the structure was conﬁrmed by
site-directed mutagenesis of IL-22BP and functional studies. The
IL-22/IL-22BP three-dimensional structure reveals for the ﬁrst time
the molecular mode of IL-22BP antagonism of IL-22 action.
2. Materials and methods
2.1. Complex crystallization, structure determination, and reﬁnement
A single crystal of the IL-22/IL-22BP complex was obtained from
a solution consisting of 10% PEG 6000 and 5%MPD [23]. A complete
data set was collected at theW01B-MX2 beam line at the Laborató-
rio Nacional de Luz Síncrotron (Campinas, São Paulo, Brazil) [24].
The IL-22/IL-22BP structure was solved by molecular replacement
using the coordinates of the IL-22/IL-22R1 complex (PBD 3DLQ).
The model was reﬁned alternating cycles of model manipulation
in COOT [25] and reﬁnement in PHENIX [26]. Stereochemical anal-
ysis was performed with PROCHECK [27]. The statistics for data
processing and model reﬁnement are given in Table 1. Buried sur-
face area was calculated using PISA [28] and PROTORP [29] servers.
Figures and the root mean square deviation (r.m.s.d.) calculations
were done using PyMOL [30]. The atomic coordinates and structure
factors of IL-22/IL-22BP complex have been deposited in the Pro-
tein Data Bank under accession code 3G9V.2.2. Cellular assays for IL-22BP and IL-22R1
To allow for its cell surface expression, the mIL-22BP open read-
ing frame (ORF) cDNA was ampliﬁed by PCR and cloned into the
pDisplay vector (Invitrogen) containing the sequence coding for
the platelet-derived growth factor receptor (PDGF-R) trans-mem-
brane domain. Mutagenesis on hIL-22R1 and mIL-22BP was per-
formed by using the GeneEditor in vitro Site-Directed
Mutagenesis System (Promega). Clones obtained were sequenced
using the DYEnamic ET Dye Terminator Kit (Amersham Biosci-
ences). For stable transfections, 5  106 BW5147 cells were elec-
troporated (270 V, 74X, 1500 lF) with 50 lg of sterile DNA in
800 ll complete medium, and selected using puromycine (1.6 lg/
mL; Sigma). Cells expressing the receptor constructs were sorted
by ﬂuorescent automatic cell sorter (FACS) analysis with a mouse
monoclonal anti-hIL-22R antibody (MH22R6.6) or a biotinylated
mouse monoclonal anti-IL-22BP (AM22BP.4), followed by ﬂuores-cein isothiocyanate (FITC)-conjugated goat anti-mouse antibody
(Becton-Dickinson) or phycoerythrin-conjugated streptavidin
(Becton-Dickinson), respectively. Proliferation assays were per-
formed as described previously [17].
3. Results and discussion
3.1. Quality of the model
We determined the crystal structure of the IL-22/IL-22BP com-
plex at 2.75 Å resolution (Table 1). There are two IL-22/IL-22BP
complexes (B/A and D/C) in the crystallographic asymmetric unit
related by a non-crystallographic twofold axis. These heterodimers
are essentially identical (0.098 Å r.m.s.d. for 285 Ca atoms), and
thereafter the coordinates of the B/A complex will be considered
for structural and comparison analyses. The ﬁnal model includes
IL-22BP residues 29–225 and 26–223 (for chains A and C, respec-
tively), IL-22 residues 38–178 and 41–179 (for chains B and D,
respectively), and 221 water molecules. Several polypeptide frag-
ments of IL-22BP (chains A and C, residues 53–55, 137–141,
177–182, 196–205) and IL-22 (chain B, residues 134–139; chain
D, residues 131–139) were not included in the ﬁnal model because
of poor or disordered electron density. The Ramachandran plot
indicated that a total of 88.8% and 11.2% of the 835 amino acid res-
idues were in the most favorable and additionally allowed regions,
respectively, and no residues were found in the disallowed regions.3.2. Overall IL-22/IL-22BP complex architecture
In the IL-22/IL-22BP complex, the IL-22 molecule folds in a com-
pact bundle of six anti-parallel a-helices, whereas the IL-22BP mol-
ecule folds in an L-shaped structure consisting of two ﬁbronectin-
III domains (FBN-III) in tandem (Fig. 1A). Each FBN-III domain con-
sists of a sandwich of two anti-parallel b-sheets formed from seven
b-strands (A, B, E and C, C0, F, and G). The N-terminal D1 domain
(residues 29–121) is connected to the C-terminal D2 domain (res-
idues 126–225) by a small 310 a-helix (residues 122–125). IL-22BP
Fig. 1. Crystallographic structure of human IL-22/IL-22BP complex. (A) Ribbon representation of the IL-22/IL-22BP complex, showing the binding interfaces (site 1a and site
1b) outlined by boxes. IL-22BP is purple blue, IL-22 is cyan, and disulﬁde bridges of IL-22BP and IL-22 are cyan and yellow, respectively. (B) Stereo view of the IL-22/IL-22BP
site 1a showing the electrostatic contacts between the side chains of IL-22BP (purple blue) and IL-22 (cyan) residues. (C) Stereo view of the IL-22/IL-22BP site 1b showing the
hydrophobic cluster of IL-22BP (purple blue) and IL-22 (cyan). Water molecules are yellow spheres, and intermolecular hydrogen bonds are shown as dashed black lines.
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similar to that described for the extracellular portion of the IL-
22R1 chain (121) [17], and 10 larger than that observed in the
interleukin-10 receptor 1 (IL-10R1) chain (115) [31].
There are two disulﬁde bridges in the IL-22BP structure: the
ﬁrst between Cys78 and Cys86, that connects strands C0 with E
(in the D1 domain), and the second that links b-strand F
(Cys206) to b-strand G (Cys227) in the D2 domain (Supplementary
Fig. S1). The ﬁrst disulﬁde bridge is structurally equivalent to
Cys71/Cys79 (IL-22R1) and Cys66/Cys74 (IL-10R2), but it is not
equivalent to Cys56/Cys75 (IL-10R1) that connects b-strands C0
with C. The second disulﬁde bridge of IL-22BP is conserved in IL-
10R1, IL-10R2, and all other class II cytokine receptors, but it is
not equivalent to the disulﬁde bridge of IL-22R1 that links b-strand
A (Cys128) to b-strand G (Cys217). Thus, there is a difference in the
Cys/Cys connectivity of the C-terminal D2 domains of IL-22BP and
IL-22R1.
Sequence alignments show that human IL-22BP has 34%, 29%,
and 30% amino acid identity with the extracellular domains of IL-
22R1, IL-10R1, and IL-10R2, respectively (Supplementary Fig. S1).
Although IL-22BP and IL-22R1 share limited amino acid sequence
identity, the three-dimensional structure of IL-22BP is topologi-
cally very similar to the extracellular portion of IL-22R1 (1.68 Å
r.m.s.d., 119 Ca atoms). IL-22BP D1 (residues 29–121) domain is
structurally most similar to D1 (residues 20–113) of IL-22R1
(0.81 Å r.m.s.d, 76 Ca atoms). On the other hand, IL-22BP D2 (res-
idues 126–225) domain exhibits considerable primary structure
differences with D2 (residues 119–228) of IL-22R1 (21% amino acid
identity), which leads to a signiﬁcant dissimilarity in their 3D
structures (3.57 Å r.m.s.d., 51 Ca atoms).
3.3. Molecular details of the IL-22/IL-22BP binding interface
IL-22BP contacts IL-22 using ﬁve binding loops (L2–L6) (Fig. 1A),
as observed for the IL-22/IL-22R1 and IL-10/IL-10R1 complexes
[17,18,31]. At the D1 domain (site 1a), IL-22BP residues within
loops L2–L4 form 16 hydrogen bond/salt bridge interactions withIL-22 residues located in the loop AB (Asp67, Thr70, Asp71,
Val72, Arg73, Glu77) and on the bend in helix F1 (Lys162,
Gly165, Glu166) (Fig. 1B). The IL-22BP residue Tyr67 dominates
the molecular recognition of IL-22 by IL-22BP. Tyr67 makes ﬁve di-
rect contacts and one water-mediated interaction with IL-22 resi-
dues, including Lys162 and Glu166 that are part of the IL-10
signature (162KAIGELDLL). In addition, three IL-22BP residues
(Lys65, Glu97, and Arg119) form ﬁve salt bridge interactions with
IL-22 residues located on the AB loop (Supplementary Table S1).
There are fewer electrostatic interactions at the D2 domain (site
1b) (Fig. 1C). IL-22BP loops L5 and L6 contact IL-22 residues located
on the beginning of helices pre-A (Phe47) and A (Thr53, Asn54,
Phe57), and the C-terminus of helix F2 (Phe171, Met172,
Arg175). The two large aromatic residues Trp123 and Trp124 of
IL-22BP interact with the hydrophobic patch formed by hydropho-
bic residues (Phe47, Phe57, Phe171, and Met172) of IL-22 and IL-
22BP residues Met215 and Leu216. In addition to hydrophobic
interactions, IL-22BP residues Glu168, Met215, and Leu216 are in-
volved in some hydrogen bond/salt bridge contacts across the site
1b interface (Supplementary Table S1).
Very recently, Jones and co-workers, used homology modeling
of the IL-22/IL-22BP complex to propose ﬁve putative interactions
at the IL-22/IL-22BP interface: Lys44/Glu168, Gln48/Met215,
Asn54/Asp217, Lys61/Glu125, and Arg175/Glu168 [18]. Our IL-
22/IL-22BP crystal structure reveals that only one of them, the salt
bridge interaction Arg175/Glu168, exists across the binding inter-
face. The other four potential hydrogen bonds do not occur as
the distances between the side chains of the correspondent resi-
dues are all greater than 5 Å.
3.4. Structural comparison of IL-22/IL-22BP and IL-22/IL-22R1 binding
interfaces
The IL-22/IL-22BP complex structure is similar to IL-22/IL-22R1
(2.70 Å r.m.s.d., 259 Ca atoms; PDB 3DLQ) and IL-22/sIL-22R1
(2.86 Å r.m.s.d., 263 Ca atoms; PDB 3DGC) crystal structures
(Fig. 2A). Upon IL-22/IL-22BP complex formation, 26 IL-22 residues
P.R. de Moura et al. / FEBS Letters 583 (2009) 1072–1077 1075and 25 IL-22BP residues bury a total surface area of 1820 Å2. Sim-
ilarly, 51 residues of the IL-22/IL-22R1 interface bury 1710 Å2 of
surface area [17]. However, 23 electrostatic contacts are formed
between IL-22 and IL-22BP, whereas only 16 hydrogen bond/salt
bridge interactions are found in the IL-22/IL-22R1 binding interface
(Fig. 2B and C).
In both IL-22/IL-22BP and IL-22/IL-22R1 complexes, site 1a ac-
counts for the majority of the total buried surface area between
IL-22 and IL-22BP (1127 Å2) or IL-22R1 (996 Å2). Moreover, site
1a contains 10 conserved hydrogen bond/salt bridge interactions
(Supplementary Table S2). These electrostatic contacts are formed
between eight IL-22 residues and IL-22BP residues Lys65, Tyr67,
Gly68, Glu97, and Arg119, which are structurally equivalent to
IL-22R1 residues Lys58, Tyr60, Gly61, Glu90, and Arg112, respec-
tively (Fig. 2B). Three of the six salt bridges found in the IL-22/IL-
22BP site 1a (Asp67/Arg119, Asp71/Lys65, Arg73/Glu97) are con-
served in the IL-22/IL-22R1 complex (Asp67/Arg112, Asp71/
Lys58, Arg73/Glu90). These conserved interactions are important
in the stabilization of both complex structures.Fig. 2. Comparison of IL-22/IL-22BP and IL-22/IL-22R1 binding interfaces. (A) Superposit
crystal structures shows their binding interfaces outlined by boxes. The IL-22BP interdo
respectively. (B and C) Site 1a (B) and site 1b (C) of superimposed IL-22/IL-22BP and IL-22
in (A). Key interacting residues are shown as sticks that are labeled red (IL-22R1) or black
and green (of IL-22/IL-22R1) spheres, and hydrogen bonds are shown as dashed black line
(E) binding interfaces with positive (blue) and negative (red) electrostatic potentials. E
potentials were mapped onto the molecular surface and contoured at ±35 kT/eV (blue/rIn addition to the electrostatic interactions, both complexes
contain a hydrophobic cluster located at site 1b, which buries
776 Å2 and 720 Å2 of IL-22/IL-22BP and IL-22/IL-22R1 interface
areas, respectively (Fig. 2C). Superposition of binary complexes re-
veals that IL-22/IL-22R1 site 1b contains a smaller hydrophobic
cluster and fewer solvent-exposed non-polar residues than IL-22/
IL-22BP site 1b. Interestingly, there is a unique salt bridge interac-
tion formed between IL-22BP residue Glu168 and IL-22 helix F2
residue Arg175. This salt bridge does not exist in the IL-22/IL-
22R1 site 1b interface because the side chain of Arg175 adopts a
different conformation to interact with Thr207 from IL-22R1. Addi-
tionally, one conserved water molecule mediates the interaction
between IL-22 residues Phe47 and Thr53 with residues Met216
(of IL-22BP) and Pro216 (of IL-22R1).
Very recently, a detailed mutagenesis study has identiﬁed four
and 12 IL-22 residues that are important for IL-22BP and IL-22R1
binding, respectively [32]. Among these IL-22 residues, Asp67,
Arg73, and Lys162 side chains are critical for optimal binding to
IL-22BP and IL-22R1, which is consistent with the result from theion of IL-22/IL-22BP (cyan/purple blue) and IL-22/IL-22R1 (yellow/red) (PDB 3DLQ)
main angle is shown. Disulﬁde bridges of IL-22BP and IL-22R1 are cyan and yellow,
/IL-22R1 structures are depicted in stereo. The color designation is the same as that
(IL-22BP and both IL-22 molecules). Water molecules are yellow (of IL-22/IL-22BP)
s. (D and E) Surface potential representation of IL-22/IL-22BP (D) and IL-22/IL-22R1
ach panel represents an ‘‘open book” view of the complex interface. Electrostatic
ed), and calculated using PyMOL APBS tools [33].
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lographic models (Fig. 2A–C).
3.5. The molecular recognition of IL-22 by IL-22BP and IL-22R1
receptors
Analysis of the IL-22/IL-22BP and IL-22/IL-22R1 binding inter-
faces showed that IL-22BP and IL-22R1 bind to similar surfaces
on IL-22 (Fig. 2A–C). Comparison of surface electrostatic potential
at the IL-22/IL-22BP and IL-22/IL-22R1 interfaces reveals good
charge complementarity at site 1a (Fig. 2D and E). Nevertheless,
there are lower electrostatic and hydrophobic complementarities
between IL-22 and IL-22R1 at the site 1b interface. An interesting
feature of the IL-22 binding interface is the presence of a shallow
cavity formed by residues within helix F1 (Lys162, Gly165,
Glu166) and loop AB (Asp67), where the hydroxyl group of Tyr67
residue from IL-22BP is inserted (Fig. 2D). IL-22BP Tyr67 is struc-
turally equivalent to IL-22R1 Tyr60, and the latter ﬁts into the
same cavity formed by the intersection between IL-22 helix F1
and loop AB (Fig. 2E). However, IL-22BP Tyr67 makes more direct
electrostatic interactions with IL-22 residues than Tyr60 of IL-
22R1 [17].
The binding of IL-22 to IL-22BP is of extremely high afﬁnity
(Kd  1 pM), in comparison with the high binding afﬁnity between
IL-22 and the extracellular domain of IL-22R1 (Kd  20 nM) [18].
Our X-ray structure of the IL-22/IL-22BP complex and its compar-
ison with IL-22/IL-22R1 reveal a number of structural differences
in the recognition of IL-22 by IL-22BP and IL-22R1 that shed light
on the differences in their binding afﬁnities. First, the number of
electrostatic interactions found at the IL-22/IL-22BP interface is
higher, as evidenced by the higher degree of charge complementar-
ity compared with the IL-22/IL-22R1 interface. Second, eight of 10
conserved electrostatic interactions are shorter in the IL-22/IL-
22BP site 1a interface, indicating that IL-22BP binds to IL-22 more
tightly. Third, IL-22BP makes more direct protein–protein interac-
tions, whereas IL-22R1 shows direct and water-mediated interac-
tions with IL-22. Finally, the IL-22/IL-22BP complex contains a
larger hydrophobic cluster centered at site 1b that contributes to
strengthen the interaction between IL-22 and IL-22BP. Thus, the
combined effects of electrostatic and hydrophobic contacts acrossFig. 3. The inﬂuence of mIL-22BP mutants in the mIL-22 binding. (A and B) Fluorescence-
cell surface expression and mIL-22 binding activities. Left panels, 105 BWIL-22BP cells fro
22BP monoclonal antibody (0.5 lg/mL) followed by phycoerythrin-conjugated streptavid
of biotinylated mIL-22 (6.8 ng/mL). The binding was detected with phycoerythrin-conjug
or mutant R112A) cells were stimulated in triplicates with various dilutions of hIL-22 for
results correspond to the mean and SD from triplicate cultures.the IL-22/IL-22BP binding interface contribute to the high binding
afﬁnity of the complex.
3.6. Determination of the IL-22BP functional epitopes by site-directed
mutagenesis
To assess the functional importance of the IL-22BP residues for
IL-22 binding, we mutated key amino acid residues located at the
complex interface using site-directed mutagenesis. Two IL-22BP
residues were chosen (Tyr67 and Arg119), due to their participa-
tion in several hydrogen bond/salt bridge interactions with the
IL-22 molecule (Fig. 1B; Supplementary Table S1). These selected
residues are structurally equivalent to Tyr66 and Arg118 residues
from murine IL-22BP (mIL-22BP). Thus, two murine mutants were
generated (Y66A and R118A) in order to test their abilities to bind
to murine IL-22 (mIL-22) in a cell-based assay. These mutations
were inserted into a cell surface version of mIL-22BP obtained by
cloning the IL-22BP ORF in frame with the PDGF-R trans-mem-
brane domain. Wild type mIL-22BP was used as an internal control.
While human and murine IL-22 share 79% amino acid identity, hu-
man IL-22BP has 67% sequence identity with its murine ortholog
(Supplementary Figs. S2 and S3). According to the amino acid se-
quence alignments, murine residues Tyr66 and Arg118 are all con-
served in human IL-22BP (hIL-22BP) and IL-22R1 (hIL-22R1).
At the IL-22/IL-22BP interface, hIL-22BP Tyr67 side chain forms
an extensive hydrogen bond network with Asp67, Val72, Lys162,
and Glu166 residues of IL-22. These interactions have their coun-
terparts in the IL-22/IL-22R1 complex, where IL-22R1 Tyr60 makes
direct and water-mediated interactions with the same IL-22 resi-
dues (Fig. 2B). In order to check the importance of Tyr67 for IL-
22/IL-22BP binding, the structurally equivalent murine residue
Tyr66 was mutated to an Ala residue. The mIL-22BP Y66A muta-
tion completely abolished mIL-22 binding (Fig. 3A). The same re-
sult was obtained for IL-22R1 mutants Y60R and Y60A that
completely failed to respond to IL-22 [17], indicating that a tyro-
sine residue at this position in IL-22R1 and IL-22BP is critical for
IL-22 binding.
Another important salt bridge found at the IL-22 molecular
interface involves IL-22 residue Asp67 and hIL-22BP residue
Arg119, which is structurally equivalent to Arg112 of IL-22R1activated cell sorting (FACS) analysis of mIL-22BP (WT or mutants Y66A and R118A)
m two independent experiments were analyzed by FACS with a biotinylated anti-IL-
in labeling. Right panels, 105 BWIL-22BP cells were analyzed by FACS for the binding
ated streptavidin. (C) Inhibition of BWhIL-22R1 cell proliferation. BWhIL-22R1 (WT
72 h and proliferation was assessed by measuring H3-thymidine incorporation. The
P.R. de Moura et al. / FEBS Letters 583 (2009) 1072–1077 1077(Fig. 2B). In order to assess the functional role of Arg119 residue for
IL-22/IL-22BP binding, the structurally equivalent murine residue
Arg118 was mutated to an Ala residue. The murine R118A point
mutant affected partially the mIL-22BP expression, but it com-
pletely abolished mIL-22 binding (Fig. 3B). When Arg112 was mu-
tated to an Ala residue, the IL-22R1 R112A mutant completely
abolished the IL-22 response, reﬂecting its importance in IL-22/
IL-22R1 binding (Fig. 3C).
Acknowledgements
This work was supported in part by FAPESP (Grants #06/00182-
8 and #06/01534-5), CNPq (Grant #154559/2006-7), as well as by
the Belgian Programme on Interuniversity Poles of Attraction initi-
ated by the Belgian State, Prime Minister’s Ofﬁce, Science Policy
Programming, by the Actions de Recherche Concertées of the Com-
munauté Française de Belgique, and by the Opération Télévie. L.D.
is a research associate with the Fonds National de la Recherche Sci-
entiﬁque, Belgium.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2009.03.006.
References
[1] Asadullah, K., Sterry, W. and Volk, H.D. (2003) Interleukin-10 therapy – review
of a new approach. Pharmacol. Rev. 55, 241–269.
[2] Renauld, J.C. (2003) Class II cytokine receptors and their ligands: key antiviral
and inﬂammatory modulators. Nat. Rev. Immunol. 3, 667–676.
[3] Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S.T., Otte, J.M.,
Diepolder, H., Marquardt, A., Jagla, W., Popp, A., Leclair, S., Herrmann, K.,
Seiderer, J., Ochsenkühn, T., Göke, B., Auernhammer, C.J. and Dambacher, J.
(2006) IL-22 is increased in active Crohn’s disease and promotes
proinﬂammatory gene expression and intestinal epithelial cell migration.
Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827–G838.
[4] Whittington, H.A., Armstrong, L., Uppington, K.M. and Millar, A.B. (2004)
Interleukin-22: a potential immunomodulatory molecule in the lung. Am. J.
Respir. Cell Mol. Biol. 31, 220–226.
[5] Ikeuchi, H., Kuroiwa, T., Hiramatsu, N., Kaneko, Y., Hiromura, K., Ueki, K. and
Nojima, Y. (2005) Expression of interleukin-22 in rheumatoid arthritis:
potential role as a proinﬂammatory cytokine. Arthritis Rheum. 52, 1037–1046.
[6] Boniface, K., Guignouard, E., Pedretti, N., Garcia, M., Delwail, A., Bernard, F.X.,
Nau, F., Guillet, G., Dagregorio, G., Yssel, H., Lecron, J.C. and Morel, F. (2007) A
role for T cell-derived interleukin 22 in psoriatic skin inﬂammation. Clin. Exp.
Immunol. 150, 407–415.
[7] Zenewicz, L.A., Yancopoulos, G.D., Valenzuela, D.M., Murphy, A.J., Karow, M.
and Flavell, R.A. (2007) Interleukin-22 but not interleukin-17 provides
protection to hepatocytes during acute liver inﬂammation. Immunity 27,
647–659.
[8] Radaeva, S., Sun, R., Pan, H.N., Hong, F. and Gao, B. (2004) Interleukin 22 (IL-22)
plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival
factor for hepatocytes via STAT3 activation. Hepatology 39, 1332–1342.
[9] Wolk, K., Kunz, S., Witte, E., Friedrich, M., Asadullah, K. and Sabat, R. (2004) IL-
22 increases the innate immunity of tissues. Immunity 21, 241–254.
[10] Laurence, A., O’Shea, J.J. and Watford, W.T. (2008) Interleukin-22: a sheep in
wolf’s clothing. Nat. Med. 14, 247–249.
[11] Zheng, Y., Danilenko, D.M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J.
and Ouyang, W. (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-
induced dermal inﬂammation and acanthosis. Nature 445, 648–651.
[12] Dumoutier, L., Van Roost, E., Colau, D. and Renauld, J.C. (2000) Human
interleukin-10-related T cell-derived inducible factor: molecular cloning and
functional characterization as an hepatocytestimulating factor. Proc. Natl.
Acad. Sci. USA 97, 10144–10149.[13] Wolk, K. and Sabat, R. (2006) Interleukin-22: a novel T- and NK-cell derived
cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev.
17, 367–380.
[14] Liang, S.C., Tan, X.Y., Luxenberg, D.P., Karim, R., Dunussi-Joannopoulos, K.,
Collins, M. and Fouser, L.A. (2006) Interleukin (IL)-22 and IL-17 are
coexpressed by Th17 cells and cooperatively enhance expression of
antimicrobial peptides. J. Exp. Med. 203, 2271–2279.
[15] Kotenko, S.V., Izotova, L.S., Mirochnitchenko, O.V., Esterova, E., Dickensheets,
H., Donnelly, R.P. and Pestka, S. (2001) Identiﬁcation of the functional
interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a
common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived
inducible factor, IL-TIF) receptor complexes. J. Biol. Chem. 276, 2725–2732.
[16] Li, J., Tomkinson, K.N., Tan, X.Y., Wu, P., Yan, G., Spaulding, V., Deng, B., Annis-
Freeman, B., Heveron, K., Zollner, R., De Zutter, G., Wright, J.F., Crawford, T.K.,
Liu, W., Jacobs, K.A., Wolfman, N.M., Ling, V., Pittman, D.D., Veldman, G.M. and
Fouser, L.A. (2004) Temporal associations between interleukin 22 and the
extracellular domains of IL-22R and IL-10R2. Int. Immunopharmacol. 4, 693–
708.
[17] Bleicher, L., de Moura, P.R., Watanabe, L., Colau, D., Dumoutier, L., Renauld, J.C.
and Polikarpov, I. (2008) Crystal structure of the IL-22/IL-22R1 complex and
its implications for the IL-22 signaling mechanism. FEBS Lett. 582, 2985–2992.
[18] Jones, B.C., Logsdon, N.J. and Walter, M.R. (2008) Structure of IL-22 bound to
its high-afﬁnity IL-22R1 chain. Structure 16, 1333–1344.
[19] Logsdon, N.J., Jones, B.C., Allman, J.C., Izotova, L., Schwartz, B., Pestka, S. and
Walter, M.R. (2004) The IL-10R2 binding hot spot on IL-22 is located on the N-
terminal helix and is dependent on N-linked glycosylation. J. Mol. Biol. 342,
503–514.
[20] Dumoutier, L., Lejeune, D., Colau, D. and Renauld, J.C. (2001) Cloning and
characterization of IL-22 binding protein, a natural antagonist of IL-10-related
T cell-derived inducible factor/IL-22. J. Immunol. 166, 7090–7095.
[21] Kotenko, S.V., Izotova, L.S., Mirochnitchenko, O.V., Esterova, E., Dickensheets,
H., Donnelly, R.P. and Pestka, S. (2001) Identiﬁcation, cloning, and
characterization of a novel soluble receptor that binds IL-22 and neutralizes
its activity. J. Immunol. 166, 7096–7103.
[22] Xu, W., Presnell, S.R., Parrish-Novak, J., Kindsvogel, W., Jaspers, S., Chen, Z.,
Dillon, S.R., Gao, Z., Gilbert, T., Madden, K., Schlutsmeyer, S., Yao, L., Whitmore,
T.E., Chandrasekher, Y., Grant, F.J., Maurer, M., Jelinek, L., Storey, H., Brender, T.,
Hammond, A., Topouzis, S., Clegg, C.H. and Foster, D.C. (2001) A soluble class II
cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc.
Natl. Acad. Sci. USA 98, 9511–9516.
[23] Watanabe, L., de Moura, P.R., Nascimento, A.S., Colau, D., Dumoutier, L.,
Renauld, J.-C. and Polikarpov, I. (2009) Crystallization and preliminary X-ray
diffraction analysis of human IL-22 bound to its soluble decoy receptor IL-
22BP. Acta Crystallogr. F 65, 102–104.
[24] Guimarães, B.G., Sanfelici, L., Neuenschwander, R.T., Rodrigues, F., Grizolli,
W.C., Raulik, M.A., Piton, J.R., Meyer, B.C., Nascimento, A.S. and Polikarpov, I.
(2009) The MX2 macromolecular crystallography beamline: a wiggler X-ray
source at the LNLS. J. Synchrotr. Rad. 16, 69–75.
[25] Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular
graphics. Acta Crystallogr. D 60, 2126–2132.
[26] Adams, P.D., Gopal, K., Grosse-Kunstleve, R.W., Hung, L.-W., Ioerger, T.R.,
McCoy, A.J., Moriarty, N.W., Pai, R.K., Read, R.J., Romo, T.D., Sacchettini, J.C.,
Sauter, N.K., Storoni, L.C. and Terwilliger, T.C. (2004) Recent developments in
the PHENIX software for automated crystallographic structure determination.
J. Synchrotr. Rad. 11, 53–55.
[27] Laskowski, R.A., MacArthur, M.W., Moss, D.S. and Thornton, J.M. (1993)
PROCHECK: a program to check the stereochemical quality of protein
structures. J. Appl. Crystallogr. 26, 283.
[28] Krissinel, E. and Henrick, K. (2007) Inference of macromolecular assemblies
from crystalline state. J. Mol. Biol. 372, 774–797.
[29] Reynolds, C., Damerell, D. and Jones, S. (2009) ProtorP: a protein–protein
interaction analysis server. Bioinformatics 25, 413–414.
[30] DeLano, W.L. (2002) The PyMOLMolecular Graphics System, DeLano Scientiﬁc,
San Carlos, CA, USA.
[31] Josephson, K., Logsdon, N.J. and Walter, M.R. (2001) Crystal structure of the IL-
10/IL-10R1 complex reveals a shared receptor binding site. Immunity 15, 35–
46.
[32] Wu, P.W., Li, J., Kodangattil, S.R., Luxenberg, D.P., Bennett, F., Martino, M.,
Collins, M., Dunussi-Joannopoulos, K., Gill, D.S., Wolfman, N.M. and Fouser, L.A.
(2008) IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed
on adjacent and overlapping surfaces of IL-22. J. Mol. Biol. 382, 1168–1183.
[33] Baker, N.A., Sept, D., Joseph, S., Holst, M.J. and McCammon, J.A. (2001)
Electrostatics of nanosystems: application to microtubules and the ribosome.
Proc. Natl. Acad. Sci. 98, 10037–10041.
